Abstract: The present invention provides sterile, storage-stable topical pharmaceutical compositions intended for application to the eye, ear or nose comprising Dexamethsone and Ciprofloxacin. The topical pharmaceutical compositions of invention comprises combination of ionic tonicity agent and non-ionic tonicity agent(s). The topical pharmaceutical compositions further comprises boric acid. The invention provides a process for preparing and sterilizing the compositions in order to reduce the amount of related compounds and impurities associated with the topical compositions on storage. The topical pharmaceutical compositions of invention found storage-stable, have easy resuspendability.

Abstract: A communication device supports leaving a message using a communication device input interface when the device is in a locked state. The communication device may be a network telephone having a display interface and a user input interface. The communication device may be configured to transition to a locked state, store a message based on input received at the locked communication device, and present the message to an intended recipient. The message may be presented to the intended recipient upon unlocking the device (e.g., stored locally and presented when the phone is unlocked), presented to the intended recipient in accordance with communication settings (e.g., delivered to an email account, cell phone, etc.), or otherwise delivered.

Abstract: The present invention relates to novel crystalline form of (4-Nitrobenzyl (4R,5S,6S)-(3-{(3S,5S)-5-[(dimethylamino)carbonyl]-1-[(4-nitrophenoxy)carbonxyl]pyrrolidin-3-yl}thio-6-[(1R)-1-hydorxyehtyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0].hept-2-ene-2-carboxylate) of compound Formula I as well as an improved process for the preparation of meropenem trihydrate of compound Formula II wherein, PNB represent P-nitro benzyl group and PNZ represent P-nitrobenzyloxycarbonyl group.

Abstract: The present invention specially relates to the crystalline form of (4-Nitrobenzyl (4R,5S,6S)-(3-{(3S,5S)-5-[(dimethylamino)carbonyl]-1-[(4-nitrophenoxy)carbonxyl]pyrrolidin-3-yl}thio-6-[(1R)-1-hydorxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0].hept-2-ene-2-carboxylate) of compound Formula I as well as an improved process for preparation of meropenem trihydrate of compound Formula II wherein PNB represents a P-nitro benzyl group and PNZ represents a P-nitrobenzyloxycarbonyl group.

Abstract: Methods and kits for determining the specificity of siRNAs for their targets are provided. Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene of interest. Finally, a method for treating genetic disorders associated with production of mutated proteins is also disclosed.

Abstract: A communication device supports leaving a message using a communication device input interface when the device is in a locked state. The communication device may be a network telephone having a display interface and a user input interface. The communication device may be configured to transition to a locked state, store a message based on input received at the locked communication device, and present the message to an intended recipient. The message may be presented to the intended recipient upon unlocking the device (e.g., stored locally and presented when the phone is unlocked), presented to the intended recipient in accordance with communication settings (e.g., delivered to an email account, cell phone, etc.), or otherwise delivered.

Abstract: Novel nucleic acid molecules encoding SA-binding proteins involved in SA-mediated disease resistance responses are disclosed. Methods of use of the nucleic acid molecules and proteins of the invention are also provided.

Abstract: Methods and kits for determining the specificity of siRNAs for their targets are provided. Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene of interest. Finally, a method for treating genetic disorders associated with production of mutated proteins is also disclosed.

Abstract: Novel nucleic acid molecules encoding SA-binding proteins involved in SA-mediated disease resistance responses are disclosed. Methods of use of the nucleic acid molecules and proteins of the invention are also provided.